Company intelligence / Profile preview

OrphoMed, Inc.

San Francisco, California, USA

Ownership: Private
Employees: ~8
Development stage: Phase 1

Overview

OrphoMed’s lead candidate, ORP‑101—a peripherally acting dimer therapeutic—received FDA Fast Track designation for IBS-D. The company leverages a proprietary dimer platform to develop novel therapies targeting visceral hypersensitivity and hypermotility. Clinical results have not been published in detail but the Fast Track status indicates promising early data and significant unmet need addressed by their approach.

Therapeutic areas: Gastroenterology
Modalities: Small molecules (specifically dimer therapeutics/conjugates)
Industry: Biotech

Drug pipeline

3 assets

ORP-101

2 more assets in the full pipeline.

Request access →

Partnerships

No major pharma partnerships disclosed; investors include Takeda Ventures which may indicate some strategic relationship.

Beyond the preview

Go deeper on OrphoMed, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OrphoMed, Inc..

Explore the full profile